Related Experiment Video
Updated: Jul 29, 2025

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Growing up with Idiopathic Pulmonary Arterial Hypertension: An Arduous Journey
Tanguy Dutilleux1, Nesrine Farhat2, Ruth Heying3
1Department of Pediatric Cardiology, University Hospital Aachen, 52074 Aachen, Germany.
Insights
Idiopathic pulmonary arterial hypertension (IPAH) is a rare, severe childhood disease. Early treatment stabilized but did not decrease pulmonary artery pressure, highlighting the need for novel therapies to improve quality of life.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Rare Diseases
Background:
- Idiopathic pulmonary arterial hypertension (IPAH) is a severe, uncommon condition affecting children.
- Clinical presentation includes non-specific symptoms like exercise intolerance and fatigue.
Observation:
- A 7-year-old boy with suspected pulmonary hypertension (PH) was diagnosed with IPAH.
- Vasoreactive testing was negative, leading to treatment with sildenafil and bosentan.
- Initial treatment stabilized pulmonary artery pressure for 5 years but did not improve quality of life.
Findings:
- The patient experienced disease progression with increased pulmonary artery pressure and supra-systemic levels.
- This deterioration necessitated enrollment in an ongoing clinical trial.
Implications:
- IPAH significantly reduces quality of life in children and carries a high mortality/morbidity burden.
- Current treatments offer limited long-term efficacy, emphasizing the need for advanced therapeutic strategies.
- Further research into novel treatments for pediatric IPAH is crucial for improving patient outcomes and quality of life.
Abstract:
Idiopathic pulmonary arterial hypertension (IPAH) is an uncommon and severe disease. We report the case of a 7-year-old boy investigated for cardiac murmur and exercise intolerance. Pulmonary hypertension (PH) was suspected at clinical examination and confirmed by echocardiography and cardiac catheterization. This case of pulmonary hypertension was classified as idiopathic given the negative etiological investigation. Vasoreactive testing with oxygen and nitric oxide was negative. Therefore, treatment with sildenafil (1.4 mg/kg/d) and bosentan (3 mg/kg/d) was initiated. This allowed the stabilization of, but not a decrease in, pulmonary artery pressure for the next 5 years, during which the patient's quality of life was significantly reduced. At a later follow-up, the estimated pulmonary pressure was found to have increased and become supra-systemic, with a consequent deterioration in the child's condition. This led to the decision to enter him into a clinical trial that is still ongoing. Idiopathic pulmonary arterial hypertension is a severe disease that can present with non-specific symptoms, such as asthenia and exercise limitation, which are important not to trivialize. The disease is associated with significantly decreased quality of life in affected children and carries a high burden in terms of mortality and morbidity. The current knowledge about IPAH in children is reviewed, with a particular focus on the future prospects for its treatment and the related quality of life of patients.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

